The phase III candidate: Can we improve the science of selection?

被引：20

作者：

Bajorin, D ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 02期

关键词：

D O I：

10.1200/JCO.2004.10.988

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：211 / 213

页数：3

共 10 条

[1] Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy [J].

Bajorin, DF ;

Dodd, PM ;

Mazumdar, M ;

Fazzari, M ;

McCaffrey, JA ;

Scher, HI ;

Herr, H ;

Higgins, G ;

Boyle, MG .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3173-3181

[2] Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group [J].

Bamias, A ;

Aravantinos, G ;

Deliveliotis, C ;

Bafaloukos, D ;

Kalofonos, C ;

Xiros, N ;

Zervas, A ;

Mitropoulos, D ;

Samantas, E ;

Pectasides, D ;

Papakostas, P ;

Gika, D ;

Kourousis, C ;

Koutras, A ;

Papadimitriou, C ;

Bamias, C ;

Kosmidis, P ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :220-228

[3] Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].

Grossman, HB ;

Natale, RB ;

Tangen, CM ;

Speights, VO ;

Vogelzang, NJ ;

Trump, DL ;

White, RWD ;

Sarosdy, MF ;

Wood, DP ;

Raghavan, D ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866

[4] A RANDOMIZED COMPARISON OF CISPLATIN ALONE OR IN COMBINATION WITH METHOTREXATE, VINBLASTINE, AND DOXORUBICIN IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA - A COOPERATIVE GROUP-STUDY [J].

LOEHRER, PJ ;

EINHORN, LH ;

ELSON, PJ ;

CRAWFORD, ED ;

KUEBLER, P ;

TANNOCK, I ;

RAGHAVAN, D ;

STUARTHARRIS, R ;

SAROSDY, MF ;

LOWE, BA ;

BLUMENSTEIN, B ;

TRUMP, D .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1066-1073

[5] A PROSPECTIVE RANDOMIZED TRIAL COMPARING MVAC AND CISCA CHEMOTHERAPY FOR PATIENTS WITH METASTATIC UROTHELIAL TUMORS [J].

LOGOTHETIS, CJ ;

DEXEUS, FH ;

FINN, L ;

SELLA, A ;

AMATO, RJ ;

AYALA, AG ;

KILBOURN, RG .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) :1050-1055

[6]

Mead GM, 1997, J CLIN ONCOL, V15, P594

[7] Phase III trial of fluorouracil, interferon alfa-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer [J].

Siefker-Radtke, AO ;

Millikan, RE ;

Tu, SM ;

Moore, DF ;

Smith, TL ;

Williams, D ;

Logothetis, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1361-1367

[8] Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:: European organization for research and treatment of cancer protocol no. 30924 [J].

Sternberg, CN ;

de Mulder, PHM ;

Schornagel, JH ;

Théodore, C ;

Fossa, SD ;

van Oosterom, AT ;

Witjes, F ;

Spina, M ;

van Groeningen, CJ ;

de Balincourt, C ;

Collette, L .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2638-2646

[9] Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial [J].

Verbel, DA ;

Kelly, WK ;

Smaletz, O ;

Regan, K ;

Curley, T ;

Heller, G ;

Scher, HI .

UROLOGY, 2003, 61 (01) :142-144

[10] Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study [J].

von der Maase, H ;

Hansen, SW ;

Roberts, JT ;

Dogliotti, L ;

Oliver, T ;

Moore, MJ ;

Bodrogi, I ;

Albers, P ;

Knuth, A ;

Lippert, CM ;

Kerbrat, P ;

Rovira, PS ;

Wersall, P ;

Cleall, SP ;

Roychowdhury, DF ;

Tomlin, I ;

Visseren-Grul, CM ;

Conte, PF .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3068-3077

← 1 →